➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Moodys
Express Scripts
Colorcon
Baxter

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FLUORODOPA F-18

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Fluorodopa F-18

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00674440 ↗ Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism Active, not recruiting University of Pennsylvania Phase 2 2004-12-01 Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these children may require surgery. In this study, researchers affiliated with the University of Pennsylvania will test how well a radioactive drug (called F-DOPA) can detect a form of hyperinsulinism that may be cured by surgery. Eligible participants in this study will have positron emission tomography (PET) scans with F-DOPA prior to surgery.
NCT00674440 ↗ Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism Active, not recruiting Children's Hospital of Philadelphia Phase 2 2004-12-01 Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these children may require surgery. In this study, researchers affiliated with the University of Pennsylvania will test how well a radioactive drug (called F-DOPA) can detect a form of hyperinsulinism that may be cured by surgery. Eligible participants in this study will have positron emission tomography (PET) scans with F-DOPA prior to surgery.
NCT01165632 ↗ Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma Active, not recruiting National Cancer Institute (NCI) N/A 2010-07-01 RATIONALE: New imaging procedures, such as fluorine F 18 fluorodopa-labeled PET scan, may help in guiding surgery and radiation therapy and allow doctors to plan better treatment. PURPOSE: This clinical trial studies fluorine F 18 fluorodopa-labeled PET scan in planning surgery and radiation therapy in treating patients with newly diagnosed high- or low-grade malignant glioma
NCT01165632 ↗ Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma Active, not recruiting Mayo Clinic N/A 2010-07-01 RATIONALE: New imaging procedures, such as fluorine F 18 fluorodopa-labeled PET scan, may help in guiding surgery and radiation therapy and allow doctors to plan better treatment. PURPOSE: This clinical trial studies fluorine F 18 fluorodopa-labeled PET scan in planning surgery and radiation therapy in treating patients with newly diagnosed high- or low-grade malignant glioma
NCT01991977 ↗ 18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy Recruiting National Cancer Institute (NCI) Phase 2 2013-12-01 This phase II trial studies how well fluorine F 18 fluorodopa (18F-DOPA)-positron emission tomography (PET) works in finding tumors in patients with newly diagnosed gliomas undergoing radiation therapy. Comparing results of diagnostic procedures done before and during radiation therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
NCT01991977 ↗ 18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy Recruiting Mayo Clinic Phase 2 2013-12-01 This phase II trial studies how well fluorine F 18 fluorodopa (18F-DOPA)-positron emission tomography (PET) works in finding tumors in patients with newly diagnosed gliomas undergoing radiation therapy. Comparing results of diagnostic procedures done before and during radiation therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fluorodopa F-18

Condition Name

Condition Name for Fluorodopa F-18
Intervention Trials
Malignant Glioma 4
Adult Anaplastic Oligodendroglioma 2
Congenital Hyperinsulinism 2
Adult Gliosarcoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fluorodopa F-18
Intervention Trials
Glioma 7
Glioblastoma 4
Ependymoma 2
Astrocytoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fluorodopa F-18

Trials by Country

Trials by Country for Fluorodopa F-18
Location Trials
United States 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fluorodopa F-18
Location Trials
Minnesota 4
Texas 2
Pennsylvania 2
Arizona 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fluorodopa F-18

Clinical Trial Phase

Clinical Trial Phase for Fluorodopa F-18
Clinical Trial Phase Trials
Phase 2 4
Phase 1/Phase 2 1
Phase 1 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fluorodopa F-18
Clinical Trial Phase Trials
Recruiting 3
Terminated 3
Active, not recruiting 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fluorodopa F-18

Sponsor Name

Sponsor Name for Fluorodopa F-18
Sponsor Trials
National Cancer Institute (NCI) 5
Mayo Clinic 4
Cook Children's Health Care System 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fluorodopa F-18
Sponsor Trials
Other 12
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Dow
Boehringer Ingelheim
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.